No Detail Found!

Impact of Paricalcitrol on Inflammatory and Anaemia Markers in Dialysis Patients.

Author(s)
Adil Manzoor Department of Nephrology King Fahd Hospital, Medina, Kingdom of, Saudi Arabia
Khalid Alwadi Department of Nephrology King Fahd Hospital, Medina, Kingdom of, Saudi Arabia
Ahmed Bhat Department of Nephrology King Fahd Hospital, Medina, Kingdom of, Saudi Arabia
Abstract
Background: The role of Vitamin D in calcium and phosphate homeostasis is renowned. The effects of vitamin D on bone metabolism have been established for long. We planned to see the effects of vitamin D analogue paricalcitrol as on mineral bone disorder in chronic kidney disease. (CKD MBD) parameters and markers of anaemia and inflammation. Method: This prospective and observational study was done at King Fahd Hospital, Medina, Saudi Arabia for 3 months from Jan to Apr 2017. Two hundred and ten (210) patients fulfilled the eligibility criteria. Paricalcitrol was given at a dose of 0.04 µg/Kg 3 times a week and parathyroid (PTH) was monitored for 3 months and subsequently the dose was titrated to the PTH levels. We looked at the relationship between paricalcitrol and anaemia markers, inflammatory markers, and erythropoietic stimulating agent dose. Results: Two hundred and ten (210) patients were studied, mean age was 50 years, 55% were males; 120 were excluded who had vitamin D level in the normal range, who received vitamin D in the recent past, with phosphate levels >2 and calcium levels >2.55 mmol/L, on calcimimmetics, parathyroidectomy cases, and patients with active infection or malignancy. Parathyroid hormone (PTH) fell significantly -166.4 (95% CI -290, -42.5, p<0.05), Transferrin saturation improved significantly (4.4% 95% CI 1.6, 7.2 p=0.003). CRP fell significantly (p<0.01). However, Hb or ESA requirement did not reach statistical significance. Conclusion: Paricalcitrol treatment is associated with improvement in secondary hyperparathyroidism in haemodialysis population. There is a signal towards improvement in markers of inflammation and anaemia but a larger Randomised Control Trial (RCT) is needed to be done.
Publication Details
Page(s) 3-6
DOI DOI not available
Published Journal: Pakistan Journal of Physiology, Volume: 14, Issue: 2, Year: 2018

Request the full text from PASTIC

References
GonzalezEA,SachdevaA,OliverDA,MartinKJ, 2004.Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study,Am J Nephrol 24 503 -10
BhanI,Bumett-BowieSA,YeJ,TonelliM,ThadhaniR., 2010.Clinical measures identify vitamin D deficiency in dialysis,Clin J Am Soc Nephrol 5 460 -7
Roj,-RiveraJ,De La PiedraC,RamosA,OrtizA,EgidoJ, 2010.,The expanding spectrum of biological actions of vitamin D. Nephrol Dial Transplant 25 2850 -65
DussoAS,TokumotoM., 2011.Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease,Kidney Int 79 715 -29
PilzS,TomaschitzA,FriedlC,AmreinK,DrechslerC,RitzE, 2011.Vitamin D status and mortality in chronic kidney disease,Nephrol Dial Transplant 26 3603 -9
GuillotX,SemeranoL,Saidenberg-Kermanac'h N,FalgaroneG,BoissierMC, 2010.Vitamin D and inflammation,Joint Bone Spine 77 552 -7
HewisonM., 2010.Vitamin D and the immune system: new perspectives on an old theme,Endocrinol Metab Clin North Am 39 365 -79
TimmsPM,MannanN,HitmanGA,NoonanK,MillsPG,Syndercombe-CourtD, 2002.Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype; mechanisms for inflammatory damage in chronic disorders,QJM 95 787 -96
AmerM,QayyumR,HydoxyvitaminD,C-, 2012.Reactive protein in asymptomatic adults (from the continuous national health and nutrition examination survey 2001 to,Am J Cardiol 109 226 -30
BertoldoF,PancheriS,ZenariS,BoldiniS,GiovanazziB,ZanattaM, 2010.Serum 2S-hydroxyvitamin D levels modulate the acute phase response associated with the first nitorogen-containing bisphosphonate infusion,J Bone Miner Res 25 447 -54
ScharlaSH,Scheidt-NaveC,LeidigG,WoitgeH,WusterC,Seibel MJ, 1996.Lower serum 25-hydroxyvitamin D is associated with increased bone resorption markers and lower bone density at the proximal femur in normal females: a population-based study,Exp Clin Endocrinal Diabetes 104 289 -92
EdaS,RoosW, 1998.Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range,J Clin Lab Anal 12 137 -44
HackengWH,LipsP,NetelenbosJC,LipsCJ, 1986.Clinical implications of estimation of intact parathyroid hormone (PTH) versus total immunoreactive PTH in normal subjects and hyperparathyroid patients,J Clin Endocrino Metab 63 447 -53
AdamsPC,ReboussinDM,PressRD,BartonJC,ActonRT,MosesGC, 2007.Biological variability of transferrin saturation and unsaturated iron-binding capacity,Am J Med 120 999 -
KandulaP,DobreM,ScholdJD,Schreiber MJ,MchrotraR,NavaneethanSD, 2011.Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials,Clin J Am Soc Nephrol 6 50 -62
DarouxM,ShenoudaM,BacriJL,LemaitreV,VanhilleP,BatailleP.,Vitamin, 2013.D2 versus vitamin D3 supplementation in hemodialysis patients; a comparative pilot study,J Nephrol 26 152 -7
IzquierdoMJ,CaviaM,MuñizP,de FranciscoAL,AriasM,SantosJ, 2012.Paricalcitol reduces oxidative stress and inflammation in haemodialysis patients,BMC Nephrol 13 159 -
LevinA,BakrisGL,MolitchM,SmuldersM,TianJ,WilliamsLA, 2007.Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease; results of the study to evaluate early kidney disease,Kidney Int 71 31 -8
Borrego UtielFJ,Bravo SotoJA,Merino PérezMJ,González CarmeloI,López JiménezV,García ÁlvarezT, 2015.Effect of paricalcitol on mineral metabolism in kidney transplant patients with secondary hyperparathyroidism,Nefrologia 35 363 -73
KorkorAB, 1987.-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure,N Engl J Med 316 1573 -7
Večerić-HalerŽ,RomoziK,AntoničM,BenedikM,PonikvarJB,PonikvarR, 2016.Comparison of the pharmacological effects of paricalcitol versus calcitriol on secondary hyperparathyroidism in the dialysis population,Ther Apher Dial 20 261 -6
KatesDM,SherrardDJ,AndressDL, 1997.Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure,Am J Kidney Dis 30 809 -13
YamamotoM,IgarashiT,MuramatsuM,FukagawaM,MotokuraT,OgataE, 1989.Hypocalcemia increases and hypercalcemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat,J Clin Invest 83 1053 -6
LlachF,MassrySG,SingerFR,KurokawaK,KayeJH,CoburnJW, 1975.Skeletal resistance to endogenous parathyroid hormone in pateints with early renal failure. A possible cause for secondary hyperparathyroidism,J Clin Endocrinol Metab 41 339 -45
FukagawaM,KazamaJJ, .Its role in renal bone disease, -
2006.,Pediatr Nephrol 21 1802 -6
KazamaJJ,GejyoF,ShigematsuT,FukagawaM., 2005.Role of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism,Ther Apher Dial 9 328 -30
KramerH,BemsJS,ChoiMJ,MartinK,RoccoMV,HydroxyvitaminD testing, 2014.and supplementation in CKD: an NKFKDOQI controversies report,Am J Kidney Dis 64 499 -509
2010.Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters,Clin J Am Soc Nephrol 5 905 -11
MoraJR,IwataM, 2008.Vitamin effects on the immune system; vitamins A and D take centre stage,Nat Rev Immunol 8 685 -98
CantornaMT,ZhuY,FroicuM,WittkeA,-dihydroxyvitaminD3, 2004.and the immune system,Am J Clin Nutr 80 1717 -20
MatilainenJM,HussoT,ToropainenS,SeuterS,TurunenMP,GyntherP, 1803.Primary effect of 1α, 25(OH)2D3 on IL-10 expression in monocytes is short-term downregulation,Biochem Biophys Acta 1276 -86
AdoriniL,PennaG,FibbiB,MaggiM. Vitamin, 2010.D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia,Ann N Y Acad Sci 1193 146 -52
HanT,RongG,QuanD,ShuY,LiangZ,SheN, 2013.Metaanalysis: the efficacy and safety of paricalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease,Biomed Res Int 320560 -
Vitamin, 2013.D supplementation affects serum high-sensitivity Creactive protein, insulin resistance, and biomarkers of oxidative stress in pregnant women,J Nutr 143 1432 -8
Blanco-RojoR,Pdrez-GranadosAM,ToxquiL,ZazoP,de la PiedraC,VaqueroMP, 2013.Relationship between vitamin D deficiency, bone remodelling and iron status in iron-deficient young women consuming an iron-fortified food,Eur J Nutr 52 695 -703
NormanAW, 2006.Minireview: vitamin D receptor: new assignments for an already busy receptor,Endocrinol 147 5542 -8
GoicoecheaM,VazquezMI,RuizMA,Gomez-CampderaF,Perez-GarciaR, 1998.Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients,Nephron 78 23 -7
KumarVA,KujubuDA,SimJJ,RasgonSA,YangPS, 2011.Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients,J Nephrol 24 98 -105
0

Citations

0

Downloads

71

Views